您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Valbenazine
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Valbenazine
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Valbenazine图片
CAS NO:1025504-45-3
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 418.57
Formula C24H38N2O4
CAS No.1025504-45-3 (free base);
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 10 mM
Water: <1 mg/mL
Ethanol: <1 mg/mL
SMILESN[C@@H](C(C)C)C(O[C@H]1[C@H](CC(C)C)CN2CCC3=CC(OC)=C(OC)C=C3[C@@]2([H])C1)=O
SynonymsValbenazine; NBI-98854; MT-5199; NBI 98854; MT5199; NBI98854; MT 5199; trade name: Ingrezza
实验参考方法
In Vitro

In vitro activity: Valbenazine, also known as NBI-98854 and MT-5199, is a potent and selective inhibitor of VMAT2 (vesicular monoamine transporter 2). Valbenazine is a prodrug of the (+)-α isomer of tetrabenazine for tardive syndrome therapy. It is effective in regulating the levels of dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines. Valbenazine is used to treat tardive dyskinesia in adults. Tardive dyskinesia is a neurological disorder characterized by involuntary movements. The clinical trials that led to FDA approval of valbenzazine were 6 weeks in duration. An industry-sponsored study has studied the use of valbenzazine for up to 48 weeks, in which it was found to be safe and effective for maintaining short-term (6 week) improvements in tardive dyskinesia.


Kinase Assay: Valbenazine, also known as NBI-98854 and MT-5199, is a potent and selective inhibitor of VMAT2 (vesicular monoamine transporter 2).


Cell Assay:

In VivoValbenazine shows a distinctive improvement in tardive dyskinesia symptoms during the successful Phase II trial
Animal model
Formulation & Dosage
References Expert Opin Investig Drugs. 2015 Jun;24(6):737-42.